On 16th September, Dr. Hung-Kai Chen, Founder & CEO of Elixiron Immunotherapeutics, shared the company’s innovative pipeline addressing one of the toughest challenges in oncology—T cell exhaustion at the Taiwan Immuno-Oncology Drug Development Forum.
 
Key Highlights
 

• EI-220 (mRNA immunotherapy): Targets T cell exhaustion with a novel design; achieved 70x stronger T cell activation and superior safety in preclinical studies. Moving toward clinical application in head & neck cancers.
• EI-012 (liver cancer antibody drug): Out-licensed to Pilatus Biosciences in a $400M deal; set to enter Phase 1 trial in 2026. Designed to block CD36-mediated fatty acid uptake, restoring T cell function in fatty liver–related liver cancer.
• Pipeline Progress: Additional clinical programs include EI-1071 (Alzheimer’s, Phase 2) and EI-001 (Vitiligo, Phase 2-ready).

 
Dr. Chen emphasized that precision immunotherapies targeting disease-driving mechanisms will shape the future of breakthrough medicines.
 
Read More, Learn More: https://news.gbimonthly.com/tw/article/show.php?num=80353
 
Follow us for more news and Taiwan biotech ecosystem updates.